Axel Sarrias
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Axel Sarrias has a total of 73 co-authors. Here are the top co-authors by number of shared publications:
- Roger Villuendas
Servicio de Cardiología, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain
8 shared publications - Antoni Bayes-Genis
Heart Institute, Hospital Universitari Germans Trias i Pujol, CIBERCV , Badalona
6 shared publications - Felipe Bisbal
ICREC Research Program, Germans Trias i Pujol Research Institute (IGTP), Badalona, Barcelona, Spain; Heart Institute (iCOR), Germans Trias i Pujol University Hospital, Badalona, Barcelona, Spain; CIBER Cardiovascular, Instituto de Salud Carlos III, Madrid, Spain
5 shared publications - Victor Bazan
Heart Institute (iCOR), Germans Trias i Pujol University Hospital
5 shared publications Damià Pereferrer
Electrophysiology Unit Cardiology Department Hospital Universitari Germans Trias i Pujol CIBERCV Univertitat Autonoma de Barcelona Badalona Spain
3 shared publications- Albert Teis
Cor, Departament de Cardiologia, Secció d'Imatge Cardiovascular, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain
2 shared publications
Latest Publications
- Open Access
- 3 June 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (11) , e040214
Initiating Empagliflozin and Sacubitril/Valsartan Early After Acute Myocardial Infarction: Mechanistic Study
Background: Empagliflozin and sacubitril/valsartan are established in heart failure treatment, but their effects after myocardial infarction (MI) are less clear. This study evaluated early empagliflozin initiation, with or without sacubitril/valsartan, on post‐MI inflammation, oxidative stress, metabolism, fibrosis, cardiac function, and ventricular tachycardia (VT) risk in a pig model. Methods: A total of 24 of 30 pigs survived the MI procedure and were subsequently randomized to receive beta‐blocker treatment alone (control‐MI), beta‐blocker+empagliflozin, or beta‐blocker+empagliflozin+sacubitril/valsartan. Immune response, metabolic profile, and cardiac function were monitored. At 30 days after MI, programmed electrical stimulation and high‐density mapping were performed and VT inducibility was assessed. Tissue samples were collected for cardiac inflammation, oxidative stress, and metabolic analyses. Results: Empagliflozin reduced circulating leukocytes at 2 and 15 days after MI ( P =0.010 and P =0.050, respectively) and decreased C‐C chemokine receptor 2+ monocytes at 15 days ( P =0.049). Nitric oxide bioavailability increased in remote myocardium ( P =0.059), along with cardioprotective liver lipids and collagen III in the myocardial scar ( P =0.023). No effect on cardiac function or VT inducibility was observed at 30 days. With empagliflozin+sacubitril/valsartan, scar collagen I decreased ( P =0.082), left ventricular compliance improved ( P =0.029), electrophysiological remodeling improved (reduced border‐zone corridors [ P =0.006] and deceleration zones [ P =0.008]), and VT inducibility decreased ( P =0.025). Conclusions: In this pig model of nonreperfused MI treated with beta‐blocker, early initiation of empagliflozin reduced inflammation, improved nitric oxide bioavailability, increased protective liver lipids, and modified scar composition without affecting cardiac function or VT risk. With empagliflozin+sacubitril/valsartan treatment, scar collagen I and VT inducibility declined and left ventricular remodeling was enhanced.
- 3 June 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (11) , e040214
Open AccessInitiating Empagliflozin and Sacubitril/Valsartan Early After Acute Myocardial Infarction: Mechanistic Study
Background: Empagliflozin and sacubitril/valsartan are established in heart failure treatment, but their effects after myocardial infarction (MI) are less clear. This study evaluated early empagliflozin initiation, with or without sacubitril/valsartan, on post‐MI inflammation, oxidative stress, metabolism, fibrosis, cardiac function, and ventricular tachycardia (VT) risk in a pig model. Methods: A total of 24 of 30 pigs survived the MI procedure and were subsequently randomized to receive beta‐blocker treatment alone (control‐MI), beta‐blocker+empagliflozin, or beta‐blocker+empagliflozin+sacubitril/valsartan. Immune response, metabolic profile, and cardiac function were monitored. At 30 days after MI, programmed electrical stimulation and high‐density mapping were performed and VT inducibility was assessed. Tissue samples were collected for cardiac inflammation, oxidative stress, and metabolic analyses. Results: Empagliflozin reduced circulating leukocytes at 2 and 15 days after MI ( P =0.010 and P =0.050, respectively) and decreased C‐C chemokine receptor 2+ monocytes at 15 days ( P =0.049). Nitric oxide bioavailability increased in remote myocardium ( P =0.059), along with cardioprotective liver lipids and collagen III in the myocardial scar ( P =0.023). No effect on cardiac function or VT inducibility was observed at 30 days. With empagliflozin+sacubitril/valsartan, scar collagen I decreased ( P =0.082), left ventricular compliance improved ( P =0.029), electrophysiological remodeling improved (reduced border‐zone corridors [ P =0.006] and deceleration zones [ P =0.008]), and VT inducibility decreased ( P =0.025). Conclusions: In this pig model of nonreperfused MI treated with beta‐blocker, early initiation of empagliflozin reduced inflammation, improved nitric oxide bioavailability, increased protective liver lipids, and modified scar composition without affecting cardiac function or VT risk. With empagliflozin+sacubitril/valsartan treatment, scar collagen I and VT inducibility declined and left ventricular remodeling was enhanced.
- 1 May 2024
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 17 (5) , e012517
Antiarrhythmic and Anti-Inflammatory Effects of Sacubitril/Valsartan on Post-Myocardial Infarction Scar
BACKGROUND: Sacubitril/valsartan (Sac/Val) is superior to angiotensin-converting enzyme inhibitors in reducing the risk of heart failure hospitalization and cardiovascular death, but its mechanistic data on myocardial scar after myocardial infarction (MI) are lacking. The objective of this work was to assess the effects of Sac/Val on inflammation, fibrosis, electrophysiological properties, and ventricular tachycardia inducibility in post-MI scar remodeling in swine. METHODS: After MI, 22 pigs were randomized to receive β-blocker (BB; control, n=8) or BB+Sac/Val (Sac/Val, n=9). The systemic immune response was monitored. Cardiac magnetic resonance data were acquired at 2-day and 29-day post MI to assess ventricular remodeling. Programmed electrical stimulation and high-density mapping were performed at 30-day post MI to assess ventricular tachycardia inducibility. Myocardial samples were collected for histological analysis. RESULTS: Compared with BB, BB+Sac/Val reduced acute circulating leukocytes ( P =0.009) and interleukin-12 levels ( P =0.024) at 2-day post MI, decreased C-C chemokine receptor type 2 expression in monocytes ( P =0.047) at 15-day post MI, and reduced scar mass ( P =0.046) and border zone mass ( P =0.043). It also lowered the number and mass of border zone corridors ( P =0.009 and P =0.026, respectively), scar collagen I content ( P =0.049), and collagen I/III ratio ( P =0.040). Sac/Val reduced ventricular tachycardia inducibility ( P =0.034) and the number of deceleration zones ( P =0.016). CONCLUSIONS: After MI, compared with BB, BB+Sac/Val was associated with reduced acute systemic inflammatory markers, reduced total scar and border zone mass on late gadolinium-enhanced magnetic resonance imaging, and lower ventricular tachycardia inducibility.
- 1 May 2024
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 17 (5) , e012517
Antiarrhythmic and Anti-Inflammatory Effects of Sacubitril/Valsartan on Post-Myocardial Infarction Scar
BACKGROUND: Sacubitril/valsartan (Sac/Val) is superior to angiotensin-converting enzyme inhibitors in reducing the risk of heart failure hospitalization and cardiovascular death, but its mechanistic data on myocardial scar after myocardial infarction (MI) are lacking. The objective of this work was to assess the effects of Sac/Val on inflammation, fibrosis, electrophysiological properties, and ventricular tachycardia inducibility in post-MI scar remodeling in swine. METHODS: After MI, 22 pigs were randomized to receive β-blocker (BB; control, n=8) or BB+Sac/Val (Sac/Val, n=9). The systemic immune response was monitored. Cardiac magnetic resonance data were acquired at 2-day and 29-day post MI to assess ventricular remodeling. Programmed electrical stimulation and high-density mapping were performed at 30-day post MI to assess ventricular tachycardia inducibility. Myocardial samples were collected for histological analysis. RESULTS: Compared with BB, BB+Sac/Val reduced acute circulating leukocytes ( P =0.009) and interleukin-12 levels ( P =0.024) at 2-day post MI, decreased C-C chemokine receptor type 2 expression in monocytes ( P =0.047) at 15-day post MI, and reduced scar mass ( P =0.046) and border zone mass ( P =0.043). It also lowered the number and mass of border zone corridors ( P =0.009 and P =0.026, respectively), scar collagen I content ( P =0.049), and collagen I/III ratio ( P =0.040). Sac/Val reduced ventricular tachycardia inducibility ( P =0.034) and the number of deceleration zones ( P =0.016). CONCLUSIONS: After MI, compared with BB, BB+Sac/Val was associated with reduced acute systemic inflammatory markers, reduced total scar and border zone mass on late gadolinium-enhanced magnetic resonance imaging, and lower ventricular tachycardia inducibility.
- Open Access
- 12 April 2024
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 26 (5)
Targeting confluent areas of slow conduction and electrogram fragmentation for atrioventricular node re-entrant tachycardia ablation
Atrioventricular nodal re-entrant tachycardia (AVNRT) is the most common re-entrant supraventricular tachycardia. The Fractionation and WaveSpeed (WS) tools, available with the Omnipolar technology (OT) and the HD-Grid mapping catheter (Abbott Medical™, Abbott Park, IL) may help in the characterization of confluent areas (CAs) of electrogram fractionation and slow conduction in the inferoseptal isthmus,1 in the search for safer AVNRT ablation targets.
- 12 April 2024
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 26 (5)
Open AccessTargeting confluent areas of slow conduction and electrogram fragmentation for atrioventricular node re-entrant tachycardia ablation
Atrioventricular nodal re-entrant tachycardia (AVNRT) is the most common re-entrant supraventricular tachycardia. The Fractionation and WaveSpeed (WS) tools, available with the Omnipolar technology (OT) and the HD-Grid mapping catheter (Abbott Medical™, Abbott Park, IL) may help in the characterization of confluent areas (CAs) of electrogram fractionation and slow conduction in the inferoseptal isthmus,1 in the search for safer AVNRT ablation targets.
- 18 July 2023
- Published by Wiley in Pacing and Clinical Electrophysiology
- Vol. 46 (8) , 939-941
Cardiac electronic implantable devices: A call for a new coding system
Over the last decades, cardiac electronic implantable devices (CEID) have incorporated a myriad of technological capabilities that are not conveniently inferred by using the conventional ICHD and NBG coding systems. We propose a new coding system (i.e., the C‐ARL‐A coding system) aimed at overcoming this important limitation.
- 18 July 2023
- Published by Wiley in Pacing and Clinical Electrophysiology
- Vol. 46 (8) , 939-941
Cardiac electronic implantable devices: A call for a new coding system
Over the last decades, cardiac electronic implantable devices (CEID) have incorporated a myriad of technological capabilities that are not conveniently inferred by using the conventional ICHD and NBG coding systems. We propose a new coding system (i.e., the C‐ARL‐A coding system) aimed at overcoming this important limitation.
- Open Access
- 1 August 2021
- Published by Elsevier in Heart Rhythm
- Vol. 18 (8) , S166
B-PO02-167 INAPPROPRIATE SINUS TACHYCARDIA IN POST-COVID-19 SYNDROME
- 1 August 2021
- Published by Elsevier in Heart Rhythm
- Vol. 18 (8) , S166
Open AccessB-PO02-167 INAPPROPRIATE SINUS TACHYCARDIA IN POST-COVID-19 SYNDROME
- Open Access
- 1 January 2021
- Published by Elsevier in JACC: Case Reports
- Vol. 3 (1) , 150-155
Atrioventricular Node Ablation to Enhance Resynchronization Therapy Response in a Patient With Complete Atrioventricular Block
- 1 January 2021
- Published by Elsevier in JACC: Case Reports
- Vol. 3 (1) , 150-155
Open AccessAtrioventricular Node Ablation to Enhance Resynchronization Therapy Response in a Patient With Complete Atrioventricular Block
- Open Access
- 1 April 2017
- Published by Elsevier in HeartRhythm Case Reports
- Vol. 3 (4) , 196-198
Iatrogenic pleuropericardial communication: A rare complication of percutaneous epicardial mapping
- 1 April 2017
- Published by Elsevier in HeartRhythm Case Reports
- Vol. 3 (4) , 196-198
Open AccessIatrogenic pleuropericardial communication: A rare complication of percutaneous epicardial mapping
- 24 November 2015
- Published by Wolters Kluwer Health in Circulation
- Vol. 132 (21) , 2035-2036
From Atrial Fibrillation to Ventricular Fibrillation and Back
- 24 November 2015
- Published by Wolters Kluwer Health in Circulation
- Vol. 132 (21) , 2035-2036
From Atrial Fibrillation to Ventricular Fibrillation and Back
- 1 June 2015
- Published by Elsevier in Revista Española de Cardiología (English Edition)
- Vol. 68 (6) , 545
Importance of Sudden Cardiac Death Risk Stratification in Hypertrophic Cardiomyopathy. Response
- 1 June 2015
- Published by Elsevier in Revista Española de Cardiología (English Edition)
- Vol. 68 (6) , 545
Importance of Sudden Cardiac Death Risk Stratification in Hypertrophic Cardiomyopathy. Response
- 1 June 2015
- Published by Elsevier in Revista Española de Cardiología (English Edition)
- Vol. 68 (6) , 492-496
Implantable Cardioverter-defibrillator Therapy for Hypertrophic Cardiomyopathy: Usefulness in Primary and Secondary Prevention
- 1 June 2015
- Published by Elsevier in Revista Española de Cardiología (English Edition)
- Vol. 68 (6) , 492-496
Implantable Cardioverter-defibrillator Therapy for Hypertrophic Cardiomyopathy: Usefulness in Primary and Secondary Prevention